Kornimate/medical-research-clean huggingface dataset:
myocardial infarction and current oral contraceptive use

Conditions: Cardiovascular Diseases; Coronary Disease; Myocardial Infarction; Heart Diseases

Summary: to assess whether current oral contraceptive (oc) use (within the previous month) increased the risk of myocardial infarction. also, to assess the combined effects of cigarette smoking and oral contraceptive use.

background: it has been established that oral contraceptive formulations used in the 1960s and 1970s increased the risks of myocardial infarction, venous thromboembolism, and stroke. oral contraceptive formulations have changed, as have prescribing practices, and there was a need for information on the effects of the newer formulations in use. myocardial infarction is the most important cardiovascular disease in terms of the incidence and mortality attributed to use of oral contraceptives; although the overall incidence of myocardial infarction is relatively low in women of childbearing ages, the incidence is not low in smokers. design narrative: a case-control design was used. the case series consisted of women 18 to 44 years of age admitted for a documented first myocardial infarction to any of 100 collaborating hospitals in massachusetts, rhode island, and pennsylvania. nurse interviewers administered standard structured questionnaires to cases and controls on drug use, race, religion, medical history and myocardial infarction risk factors. information was collected on: cigarette smoking; histories of hypertension, diabetes mellitus, angina, abnormal plasma lipids; reproductive and menstrual histories; alcohol and coffee consumption; personality type using the framingham type a scale; family history of myocardial infarction; exercise; education and occupation of the patient and her spouse. information was also obtained on the timing and duration of oral contraceptive use. the effect of oral contraceptive use was considered among nonsmokers, light smokers, and heavy smokers. individual oral contraceptive formulations were classified according to dosage and type of estrogen, formulation type, and other groupings. multiple logistic regression analysis with fitting of the regression equations by the method of maximum likelihood was used for simultaneous control of all potential confounding factors. the study was renewed in 1995 to continue data collection to establish the effect of triphasic ocs on mi risk, with particular attention to the joint effect with heavy smoking. the new data collection also permitted more definitive analysis of the effect of monophasic ocs. triphasic formulations have become popular and in 1995 accounted for about half of oc use. there were not enough users of triphasic ocs in the present study for informative analysis, nor were there any data from other studies on this issue. the study ended in december, 1999. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
myocardial infarction and periodontitis: periodontal health intervention.

Conditions: Acute Myocardial Infarction (AMI); Periodontal Disease

Summary: the aim of this study is to establish a shared database of acute myocardial infarction patients with periodontitis, to clarify the clinical benefits of periodontitis intervention on acute myocardial infarction patients through simulated rct study, and to establish a high-level database of acute myocardial infarction patients with periodontitis, so as to promote the application of oral health intervention in clinical practice.


Eligibility criteria:
inclusion criteria: * 1)patients diagnosed with st-segment elevation myocardial infarction (stemi). 2)patients with severe periodontal disease, defined as: * 5 teeth with clinical attachment loss (cal) ≥ 4 mm. * subgingival probing depth (pd) ≥ 6 mm. ③≥ 8 teeth with gingival bleeding on probing (bop). 3）age ≥30 years. 4）written informed consent provided. exclusion criteria: * 1) under 30 years old; 2) hiv positive, chronic inflammation, tumor disease, drug dependence, use of anticonvulsants, use of immunosuppressive agents, pregnancy, and lactation; 3) significant tooth loss (number of remaining teeth \ 10 days), new myocardial infarction before randomization, and stent thrombosis; 5) refusal to sign informed consent.
clinical evaluation of the iona test for non-invasive pre natal screening in twin pregnancies

Conditions: Down Syndrome; Patau Syndrome; Edward's Syndrome

Summary: the purpose of this study is to evaluate the performance of the iona® test which is a non-invasive prenatal test (nipt) for down's syndrome and other chromosomal abnormalities in twin pregnancies, from a maternal blood sample.

350 low risk and 150 high risk women with twin pregnancies will be recruited to produce a large cohort evaluation the use of the iona test in twin pregnancies for downs, edwards and patau syndrome. reserve samples will also be used to further develop the test for other chromosomal abnormalities.

Eligibility criteria:
inclusion criteria: * currently pregnant with twin foetuses at time of entry to study * have had or are about to have a conventional screening test (combined/quad test, ultrasound scan or other nipt) * if identified as high risk, intend to undergo prenatal invasive diagnosis and/or undergoing invasive prenatal therapy such as laser treatment for ttts where a sample of amniotic fluid is taken for karyotyping. exclusion criteria: * participant herself has down syndrome or other chromosomal abnormality
study of rmc-9805 in participants with kras g12d-mutant solid tumors

Conditions: Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Advanced Solid Tumors

Summary: this study is to evaluate the safety and tolerability of rmc-9805 as monotherapy and in combination with rmc-6236 in adults with kras g12d-mutant solid tumors.

this is an open-label, multicenter, phase 1/1b study of rmc-9805, a selective and orally bioavailable kras g12d(on) inhibitor, in subjects with krasg12d-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics (pk), and preliminary clinical activity. the study consists of two arms: rmc-9805 monotherapy arm and rmc-9805 plus rmc-6236 combination arm. both arms consist of two parts: part 1- dose exploration and part 2- dose expansion.

Eligibility criteria:
inclusion criteria: * pathologically documented, locally advanced or metastatic solid tumor with a kras g12d-mutation * received and progressed or been intolerant to prior standard therapy (including targeted therapy) appropriate for tumor type and stage * ecog performance status 0 or 1 * adequate organ function exclusion criteria: * primary central nervous system (cns) tumors * known or suspected leptomeningeal or active brain metastases or spinal cord compression * known or suspected impairment of gastrointestinal function that may prohibit ability to swallow or absorb an oral medication * participant was previously treated with an investigational kras g12d inhibitor, pan- or multi-ras inhibitor, or had prior therapy with any direct ras-targeted therapy (eg, degraders and inhibitors) other inclusion/exclusion criteria may apply.

Keywords: kras g12d (on) nsclc crc pdac non-small cell lung cancer lung cancer colorectal cancer colon cancer pancreatic cancer metastatic cancer pancreatic ductal adenocarcinoma pancreatic neoplasms colorectal neoplasms gastrointestinal neoplasms kras colonic neoplasms
parotid-sparing imrt for nasopharyngeal cancer

Conditions: Nasopharyngeal Cancers; Intensity Modulated Radiotherapy With Chemotherapy

Summary: in the treatment of nasopharyngeal cancers, to determine the incidence of high grade (≥g2) subjective xerostomia at 1 year.

the purpose of this study was to determine the feasibility in delivering induction chemotherapy and concomitant chemotherapy with imrt in the treatment of locally advanced nasopharyngeal cancers and to determine the incidence of high grade (≥g2) subjective xerostomia at 1 year.

Eligibility criteria:
inclusion criteria: * nasopharyngeal cancers exclusion criteria: * patients \<16 years old or with a previous malignancy other than non-melanomatous skin cancer were excluded
does the use of continuous glucose monitoring (cgm) in the immediate postpartum period in women with pregestational diabetes admitted to the hospital decrease hypoglycemic episodes

Conditions: Pregestational Diabetes

Summary: this study will examine whether continuous glucose monitoring in patients hospitalized in the immediate postpartum period is more effective than traditional point of care glucose testing in identifying patients with hypoglycemia.

this is a prospective cohort study of women with type 1 and type 2 diabetes in the postpartum period. after obtaining informed consent, a cgm device (dexcom sensor and transmitter) will be placed by research personnel upon presentation to labor or in prenatal clinic if seen within 3 days of planned induction of labor or planned cesarean section. patient will be assisted in getting the dexcom g6 app on their cell phone to be the receiver of glucose data. patients who are currently using the dexcom cgm for routine monitoring of their glucoses, will be allowed to continue using their own sensor and transmitter. upon presentation to labor and delivery, patients will be assisted in activating the share app on their cell phone. labor and delivery nursing staff will be given a samsun phone with the follow app in order to receive glucose data. the samsung phone will be transferred to the mother/baby unit with the patient after delivery. glucose values from the cgm device will then be available to nursing through the samsung phone. nursing will be able to see current glucose data on their patient and would receive alarms to indicate hypoglycemia or impending hypoglycemia. nursing will be provided with instructions for how to access the cgm follow app and how to appropriately respond to the alarms. nursing will continue to perform standard of care blood glucose monitoring per routine protocol but will also obtain a finger stick to validate a blood glucose level whenever a low cgm alarm sounds. low blood glucose values \<70 mg/dl will be treated per local institutional nursing policy. monitoring of glucose levels through the cgm device will continue throughout their postpartum hospital stay. this is typically 2 days for a vaginal delivery, 3 days for a cesarean section. patients who do not use cgm as part of their routine care, will have their cgm sensor and transmitter removed prior to discharge from the hospital. following discharge from the hospital, there will be no additional long term follow-up. data we plan to collect for analysis includes: type of diabetes (dm1/dm2), point of care glucose values, number of hypoglycemic events, number of times treated for hypoglycemia.

Eligibility criteria:
inclusion: 1- individuals in the third trimester of pregnancy admitted to the hospital with diabetes type 1 or diabetes type 2, own a smart device (which will serve as a receiver for the cgm device) exclusion: 1. patients less than 18 years of age 2. non-english speaking patients 3. gestational diabetes 4. extensive skin changes/diseases that inhibit wearing a sensor on normal skin, known allergy to adhesives

Keywords: postpartum type 1 diabetes type 2 diabetes continuous glucose monitor
one month performance comparison between two commercially available silicone hydrogel lenses

Conditions: Myopia

Summary: the purpose of this study is to compare the performance of two commercially marketed contact lenses when worn for up to one month in a daily wear modality.


Eligibility criteria:
inclusion criteria: * habitual spherical soft contact lens wearer who wears a contact lens brand with a recommended replacement schedule of 2 weeks or greater. * have a need for correction in both eyes and be correctable to at least 20/40 distance vision in each eye at the dispense of study lenses. * willing and able to wear spherical contact lenses within the available range of powers. * wears contact lenses at least 5 days per week and at least 10 hours per day, removing them nightly. * other protocol-defined inclusion criteria may apply. exclusion criteria: * eye injury or surgery within twelve weeks prior to enrollment. * currently enrolled in any clinical trial. * any use of medications for which contact lens wear could be contraindicated, as determined by the investigator. * astigmatism of 1.00d or more. * currently wearing contact lenses in a daily disposable modality. * currently wearing air optix aqua or acuvue advance plus contact lenses. * currently sleeping overnight in contact lenses on an occasional or extended wear basis. * other protocol-defined exclusion criteria may apply.
effects of low-intensity blood flow restriction training in normoxia and hypoxia conditions

Conditions: Hypoxia, Altitude; Blood Flow Restriction; Resistance Training

Summary: one approach to significantly reducing resistance training intensity while maintaining effectiveness in muscle mass and strength development involves conducting training sessions under hypoxic conditions. this is likely due to heightened physiological responses. while sports science research indicates a substantial impact of hypoxic conditions on immediate increases in metabolic stress and augmented hormonal responses, recent findings suggest that the role of their influence on skeletal muscle adaptations post-resistance training under hypoxic conditions remains unknown. additionally, there is a lack of reports on whether the type of hypoxia applied via blood flow restriction or chamber differentiates the increase in secretion of these catecholamines in both immediate and long-term aspects.


Eligibility criteria:
inclusion criteria: * regularly physically active (at least 30 mins of structured exercise 3 times per week), * sea-level natives, * experienced in resistance training (at least one year of experience in regular resistance exercise) exclusion criteria: * presence of any medical risk factors to exercise and/or exposure to altitude * presence of any medical condition that would make the protocol unreasonably hazardous for the participant * smokers
hysteroscopic cryomyolysis for the treatment of submucosal leiomyomata

Conditions: Uterine Fibroids; Leiomyoma; Menorrhagia

Summary: the purpose of the current study is to evaluate the technical success, safety and procedure feasibility of hysteroscopic cryoablation treatment of symptomatic uterine fibroids in women who do not desire further pregnancies using galil medical's 17-gauge 400mm argon-based cryoablation needles

currently there are no optimal methods for treating symptomatic uterine fibroids. existing therapeutic options are conservative (medications), invasive (e.g., hysterectomy, surgical myomectomy), or minimally invasive (uterine artery embolization, or myolysis). fibroid ablation using cryogenic energy, known as cryoablation, offers a potential alternative method of fibroid treatment. cryotherapy is a well-established technique for the treatment of various benign and malignant conditions. cryoablation has been described for the treatment of prostate cancer, renal cell carcinoma, liver tumors and benign and malignant breast tumors. galil medical's proposed feasibility study is looking to examine the technical success, safety and feasibility of a hysteroscopic approach for the treatment of symptomatic fibroids. this technique involves the insertion and placement of galil medical's 17-gauge cryoablation needle(s)guided by a hysteroscopic device. ultrasound provides real-time monitoring of the needle insertion, placement and iceball propagation during the cryoablation procedure. this treatment offers the patient to preserve her uterus by a minimally invasive procedure. the type of the fibroids intended for treatment (type ii submucous myomas)are often very difficult to completely and safely remove hysteroscopically and are often treated through an open or laparoscopic procedure. a hysteroscopic procedure does not involve intraperitoneal intervention and is therefore expected to be associated with less intra-operative and post-operative complications. the recovery from hysteroscopic cryoablation is expected to be fast with only minimal self resolving discomfort. the patient should be able to return to her normal activity within 24-48 hours.

Eligibility criteria:
inclusion criteria: * primary complaint is excessive bleeding * subject is able to understand and give informed consent for participation in the study * pre-menopausal woman between the ages of 30 and 50 (inclusive) * has completed childbearing and not contemplating future fertility * has symptomatic uterine fibroids * fibroids type, size, location and number * 1 submucosal fibroid * type i and type ii fibroids * 2 to 4cm * using contraception to prevent pregnancy exclusion criteria: * any evidence of known or suspected infection or pre-malignancy/malignancy * desire for future child bearing * fibroids * size \> 4cm * 2 or more submucosal fibroids * fibroid distance from the serosa is less than 1 cm

Keywords: uterine fibroids leiomyoma menorrhagia hysteroscopic cryoablation minimally invasive
the impact of myofascial therapy on connective tissue

Conditions: Painful; Fascial Manipulation; Fascia; Pain; Myofascial Pain; Myofascial; Myofascial Dysfunction

Summary: the study involved patients who suffered from myofascial pain caused occupational or sports overloads or muscle strains caused by sports or improper preparation for physical activity. the patients had not been previously treated for this reason. the only form of therapy was self-administered over-the-counter painkillers and ointments. due to lack of relief, patients received one of two types of treatments, myofascial therapy or deep tissue massage. each group was divided into three subgroups, depending on the location of the symptoms: arm, forearm, calf. the patients received three treatments on alternate days. ultrasound imaging examination was performed by a physiotherapist, qualified to assess soft tissues using an usg. two measurements were taken, before and seven days after therapy. to standardise the assessment, ultrasound imaging protocol was used. the thickness of the fascia was measured by imagej software. the aim of the study was an ultrasound imaging assessment of connective tissue of patients undergone myofascial therapy.


Eligibility criteria:
inclusion criteria: * undergone myofascial therapy * undergone deep tissue massage * patients with pain of musculoskeletal origin * without contraindications to myofascial therapy * without neurological diseases * voluntary consent to participate in the study exclusion criteria: * resignation from the study * lack of patient consent * cancers * disturbed continuity of skin tissue at the examination site * previous surgical procedures at the study site * large vascular changes * inflammatory changes in the examined areas of the body * sensory disturbances in the examined body areas * resignation from therapy * changing the type of therapy
rapid amniotic fluid (af) test and a non-invasive vaginal fluid (vf) test

Conditions: Intra-Amniotic Infection of Foetus

Summary: a multi-centered, prospective study, involving pregnant women presenting to the labor and delivery unit of collaborating clinical study sites with preterm labor and intact amniotic membranes with and without suspected intra-amniotic infection (iai).

a study on patients in preterm labor for whom the managing physician plans to perform amniocentesis to evaluate for possible infection using conventional, currently available methods. vaginal fluid will be collected and analyzed and amniotic fluid will also. these tests will be run remotely and not reported to the clinician.

Eligibility criteria:
inclusion criteria: 1. subject is ≥ 18 years of age 2. subject has singleton gestation 3. subject has fetus with gestational age ≥ 22 0/7 weeks and ≤ 33 6/7 weeks 4. subject has had evidence of spontaneous preterm labor as evidenced by documented regular uterine contractions (≥4 per hour) and one or more of the following: 1. cervical dilation \> 2cm 2. cervical length of ≤25 mm via transvaginal ultrasound 5. subject has onset of contractions was within 48 hours of enrollment in the study 6. subject has documented intact amniotic membranes 7. subject's care provider plans to perform an amniocentesis procedure - exclusion criteria: * 1. subject has documented ruptured amniotic membranes 2. subject has a fetus with major fetal or genetic anomaly or chromosomal aneuploidy 3. subject has maternal or fetal indication for preterm birth (e.g., pre-eclampsia) 4. subject is unable to provide written informed consent 5. subject has evidence of non-reassuring fetal heart rate tracing requiring immediate delivery 6. subject has vaginal bleeding within the past 24 hours 7. subject has advanced labor (cervix \>4 cm dilated) 8. subject has hiv, hepatitis 9. subject has not been enrolled previously in this study and/or is participating in another study (that in the opinion of the investigator) may interfere with participation in this study
zoomit-fmri identifies language functional cortex

Conditions: Glioma

Summary: this study was designed to collect a series of patients with gliomas which were involved in language related cortex to analyze difference accuracy of language related cortex localization between bold-fmri and zoomit-fmri.

gliomas can cause language dysfunction when they are involved in language related cortex. however, tumor resection also have risk to lead postoperatively language function deficits if destroy patients' language related cortex when tumor removed. hence, it is important for neurosurgeon to realize the situation of patients' language related cortex locations in order to determine personal operative protocol. the blood oxygen level dependent fmri (bold-fmri) is a prevalent preoperative method to localization language related cortex. it shows language relevant cortex by the change of blood oxygen level when patients cooperate to finish language tasks. the advantage of bold-fmri includes higher time and spatial resolution, higher sensitivity, non-invasive. however, its accuracy of localization has not been satisfactory because neurovascular uncoupling. the zoomit-fmri is a novel technic which is evolved from conventional bold-fmri to localize language functional cortex.the advantage of zoomit-fmri is smaller field of view (fov) and higher spatial resolution comparing with bold-fmri which helps to reduce other region of brain interference and elevate accuracy of localizations. in this study, the investigators plan to enroll 60 patients, whose gliomas are involved in language related cortex, to acquire their bold-fmri and zoomit-fmri data in order to analyze their difference in the accuracy of language related cortex localization.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; 2. no history of surgical treatment or radiotherapy; 3. no contraindication to mri scanning; 4. agreeable to receive the fmri scanning and awake craniotomy with dcs exclusion criteria: 1. basing on the anatomic mri, the distance from the tumor to the hand-knob area lower than 20 mm; 2. disable to finish the task of clenching fist during fmri scanning.

Keywords: language functional cortex zoomit-fmri